{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:25:45Z","timestamp":1792689945618,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1053\/j.gastro.2019.04.011","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T11:57:46Z","timestamp":1555329466000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":267,"title":["Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics"],"prefix":"10.1053","volume":"157","author":[{"given":"Carlo A.","family":"Fallone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven F.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2019.04.011_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"issue":"6 Suppl","key":"10.1053\/j.gastro.2019.04.011_bib2","doi-asserted-by":"crossref","first-page":"s113","DOI":"10.1016\/S0016-5085(97)80023-6","article-title":"Editorial: can therapy ever be denied for Helicobacter pylori infection?","volume":"113","author":"Graham","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2019.04.011_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2019.04.011_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2019.04.011_bib7","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","article-title":"Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis","volume":"99","author":"Ford","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2019.04.011_bib8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","article-title":"Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis","volume":"150","author":"Lee","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/gut.41.1.8","article-title":"Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group","volume":"41","year":"1997","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2019.04.011_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1155\/1998\/170180","article-title":"Consensus Conference Participants. Canadian Helicobacter pylori Consensus Conference","volume":"12","author":"Hunt","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2019.04.011_bib11","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.04.011_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hel.12052","article-title":"Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy","volume":"18","author":"Liao","year":"2013","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2019.04.011_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2015.02.005","article-title":"Antibiotic resistance of Helicobacter pylori among male United States veterans","volume":"13","author":"Shiota","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.04.011_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10620-014-3365-2","article-title":"Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy","volume":"60","author":"Gisbert","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2019.04.011_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cgh.2014.10.036","article-title":"High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection","volume":"13","author":"Yang","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.04.011_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.04.011_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ACI.0000000000000173","article-title":"Penicillin allergy: optimizing diagnostic protocols, public health implications, and future research needs","volume":"15","author":"Macy","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1053\/j.gastro.2019.04.011_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: a worldwide challenge","volume":"387","author":"Laxminarayan","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.04.011_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2019.04.011_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/apt.14597","article-title":"Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains","volume":"47","author":"Gatta","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.04.011_bib23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3201\/eid1006.030744","article-title":"Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States","volume":"10","author":"Duck","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1053\/j.gastro.2019.04.011_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2017.01.028","article-title":"The AGA\u2019s Fecal Microbiota Transplantation National Registry: an important step toward understanding risks and benefits of microbiota therapeutics","volume":"152","author":"Kelly","year":"2017","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2019.04.011_bib25","first-page":"S875","article-title":"Pan-European registry on H.\u00a0pylori management (HP-EUREG)","volume":"150","author":"McNicholl","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","article-title":"Asian Pacific Alliance on Helicobacter and Microbiota. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis","volume":"2","author":"Kuo","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.04.011_bib27","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1053\/j.gastro.2018.10.012","article-title":"Antibiotic resistance is the key element in treatment of Helicobacter pylori infection","volume":"155","author":"M\u00e9graud","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.04.011_bib29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2019.04.011_bib30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2018.06.047","article-title":"Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection","volume":"155","author":"Liou","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/ajg.2017.154","article-title":"ACG and CAG clinical guidelines: management of dyspepsia","volume":"112","author":"Moayedi","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2019.04.011_bib32","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1097\/MJT.0000000000000389","article-title":"Role of bismuth in the eradication of Helicobacter pylori","volume":"24","author":"Alkim","year":"2017","journal-title":"Am J Ther"},{"issue":"F1000 Faculty Rev","key":"10.1053\/j.gastro.2019.04.011_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.12688\/f1000research.8598.1","article-title":"The role of acid inhibition in Helicobacter pylori eradication","volume":"5","author":"Scott","year":"2016","journal-title":"F1000Res"},{"key":"10.1053\/j.gastro.2019.04.011_bib34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2016.1178065","article-title":"Helicobacter pylori therapy: a paradigm shift","volume":"14","author":"Graham","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1053\/j.gastro.2019.04.011_bib35","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.cgh.2018.03.013","article-title":"Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States","volume":"16","author":"El-Serag","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.04.011_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/2050640615617358","article-title":"Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events","volume":"4","author":"McFarland","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2019.04.011_bib37","doi-asserted-by":"crossref","first-page":"9379480","DOI":"10.1155\/2018\/9379480","article-title":"What roles do probiotics play in the eradication of Helicobacter pylori? Current knowledge and ongoing research","volume":"2018","author":"Song","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"10.1053\/j.gastro.2019.04.011_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11938-018-0206-y","article-title":"Potent acid suppression with PPIs and P-CABs: what\u2019s new?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr Treat Options Gastro"},{"key":"10.1053\/j.gastro.2019.04.011_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3164\/jcbn.17-128","article-title":"Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study","volume":"63","author":"Ohkuma","year":"2018","journal-title":"J\u00a0Clin Biochem Nutr"},{"key":"10.1053\/j.gastro.2019.04.011_bib40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.gastro.2018.01.018","article-title":"Update on the use of vonoprazan: a competitive acid blocker","volume":"154","author":"Graham","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib41","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.04.011_bib42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1523-5378.2002.00105.x","article-title":"The effects of nocturnal acid breakthrough on Helicobacter pylori eradication","volume":"7","author":"Kim","year":"2002","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2019.04.011_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","article-title":"Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy","volume":"12","author":"Sugimoto","year":"2007","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2019.04.011_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.04.011_bib45","doi-asserted-by":"crossref","first-page":"e12495","DOI":"10.1111\/hel.12495","article-title":"Systemic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"issue":"Suppl","key":"10.1053\/j.gastro.2019.04.011_bib46","first-page":"S877","article-title":"Dual therapy with vonoprazan and amoxicillin is as effective as standard PPI-based triple therapy with amoxicillin and clarithromycin or metronidazole in Japan","volume":"150","author":"Furuta","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2019.04.011_bib47","first-page":"S927","article-title":"Vonoprazan-based dual therapy with amoxicillin is as effective as the triple therapy for the eradication of H pylori","volume":"154","author":"Furuta","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib48","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.3390\/cancers11010116","article-title":"Vonoprazan-based third -line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori","volume":"11","author":"Saito","year":"2019","journal-title":"Cancers"},{"key":"10.1053\/j.gastro.2019.04.011_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.micpath.2018.05.037","article-title":"An in silico study: novel targets for potential drug and vaccine design against drug resistant H.\u00a0pylori","volume":"122","author":"Pasala","year":"2018","journal-title":"Microb Pathog"},{"key":"10.1053\/j.gastro.2019.04.011_bib50","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/07391102.2017.1302361","article-title":"Functional elucidation of hypothetical proteins for their indispensable roles toward drug designing targets from Helicobacter pylori strain HPAG1","volume":"36","author":"Singh","year":"2018","journal-title":"J\u00a0Biomol Struct Dyn"},{"key":"10.1053\/j.gastro.2019.04.011_bib51","doi-asserted-by":"crossref","first-page":"e2003887","DOI":"10.1371\/journal.pbio.2003887","article-title":"Metallochaperone UreG serves as a new target for design of urease inhibitor: a novel strategy for development of antimicrobials","volume":"16","author":"Yang","year":"2018","journal-title":"PLoS Biol"},{"key":"10.1053\/j.gastro.2019.04.011_bib52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/138161210790361407","article-title":"Anti-infective strategies of the future: is there room for species-specific antibacterial agents?","volume":"16","author":"Then","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.gastro.2019.04.011_bib53","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(97)70155-0","article-title":"A\u00a0standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain","volume":"112","author":"Lee","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.04.011_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1242\/dmm.027649","article-title":"Helicobacter pylori-induced gastric pathology: insights from in\u00a0vivo and ex\u00a0vivo models","volume":"10","author":"Burkitt","year":"2017","journal-title":"Dis Model Mech"},{"key":"10.1053\/j.gastro.2019.04.011_bib55","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/S0140-6736(03)14885-4","article-title":"Antibiotic development pipeline runs dry. New drugs to fight resistant organisms are not being developed, experts say","volume":"362","author":"Nelson","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.04.011_bib56","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4161\/hv.7.11.17655","article-title":"H.\u00a0pylori vaccines: why we still don't have any","volume":"7","author":"Zhang","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1053\/j.gastro.2019.04.011_bib57","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.gtc.2015.05.013","article-title":"Current status and prospects for a Helicobacter pylori vaccine","volume":"44","author":"Blanchard","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2019.04.011_bib58","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2468-1253(18)30125-0","article-title":"Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomized, placebo-controlled phase 1\/2 study","volume":"3","author":"Malfertheiner","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.04.011_bib59","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.04.011_bib60","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(15)60579-7","article-title":"At last, vaccine-induced protection against Helicobacter pylori","volume":"386","author":"Sutton","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.04.011_bib61","article-title":"Status of vaccine research and development for Helicobacter pylori","author":"Sutton","year":"2018","journal-title":"Vaccine"},{"key":"10.1053\/j.gastro.2019.04.011_bib62","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1128\/JCM.00506-17","article-title":"A\u00a0novel stool\u00a0PCR test for Helicobacter pylori may predict clarithromycin resistance and eradication of Infection\u00a0at a high rate","volume":"55","author":"Beckman","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2019.04.011_bib63","doi-asserted-by":"crossref","first-page":"e12515","DOI":"10.1111\/hel.12515","article-title":"Diagnosis of Helicobacter pylori infection","volume":"23","author":"Skrebinska","year":"2018","journal-title":"Helicobacter"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851935704X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851935704X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:21:46Z","timestamp":1758036106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650851935704X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S001650851935704X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2019.04.011","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2019.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}